TEVA250516C14000
- 2.94
- -1.16-28.29%
Teva Pharmaceutical Industries Newsroom
Teva Pharmaceuticals Raised to Overweight From Neutral by JP Morgan
Teva Pharmaceutical Indus Analyst Ratings
J.P. Morgan Upgrades Teva Pharmaceutical Industries(TEVA.US) to Buy Rating, Announces Target Price $23
Leader Capital Markets Sticks to Their Buy Rating for Teva (TEVA)
Teva Pharmaceutical Indus Analyst Ratings
BofA Securities Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Raises Target Price to $22
Research Alert: Teva Reports Q1 Eps Beat With Solid Revenue Growth By Austedo
Neurocrine Biosciences' Ingrezza Q1 Sales Prove Resilient, Analysts Boost Price Target
HSBC Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Raises Target Price to $20
BofA Securities Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Maintains Target Price $20
BofA Securities Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Maintains Target Price $20
Piper Sandler Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Maintains Target Price $30
Teva Pharmaceutical Indus Analyst Ratings
BofA Securities Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Cuts Target Price to $20
Piper Sandler Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Maintains Target Price $30
BofA Securities Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Maintains Target Price $23
Barclays Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Maintains Target Price $26
Argus Research Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Announces Target Price $20
Piper Sandler Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Maintains Target Price $30
Barclays Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Cuts Target Price to $26